NICE rejects oral psoriasis treatment

Apremilast (Otezla) should not normally be prescribed on the NHS for chronic plaque psoriasis, NICE has decided.

Further information
NICE technology appraisal TA368

The PDE4 inhibitor is not recommended for moderate to severe chronic plaque psoriasis in adults whose psoriasis has not improved with other treatments, who have had side-effects with these treatments in the past, or who cannot have them.

NICE concluded that the incremental cost-effectiveness ratios for apremilast in the treatment of moderate and severe psoriasis were not within the range considered to indicate a cost-effective use of NHS resources.

Prescribers treating patients with apremilast should discuss alternative treatment options with the patients and continue prescribing apremilast until it is considered appropriate to stop.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases